These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17928052)

  • 41. Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia.
    Ahmad E; Steinberg SM; Goldin L; Hess CJ; Caporaso N; Kreitman RJ; Wiestner A; Wilson W; White T; Marti G; Stetler-Stevenson M
    Cytometry B Clin Cytom; 2008 Jul; 74(4):221-6. PubMed ID: 18431797
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human leukocyte antigen class II allele association to disease progression in Iranian patients with chronic lymphocytic leukemia.
    Hojjat-Farsangi M; Jeddi-Tehrani M; Amirzargar AA; Razavi SM; Sharifian RA; Rabbani H; Shokri F
    Hum Immunol; 2008 Oct; 69(10):666-74. PubMed ID: 18722491
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discordance of ZAP-70 in patients with chronic lymphocytic leukemia.
    Chaar BT; Schergen AK; Grosso LE
    Int J Lab Hematol; 2008 Feb; 30(1):36-40. PubMed ID: 18190465
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion.
    Joshi AD; Dickinson JD; Hegde GV; Sanger WG; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
    Cancer Genet Cytogenet; 2007 Jan; 172(2):120-6. PubMed ID: 17213020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis.
    Cavazzini F; Hernandez JA; Gozzetti A; Russo Rossi A; De Angeli C; Tiseo R; Bardi A; Tammiso E; Crupi R; Lenoci MP; Forconi F; Lauria F; Marasca R; Maffei R; Torelli G; Gonzalez M; Martin-Jimenez P; Maria Hernandez J; Rigolin GM; Cuneo A
    Br J Haematol; 2008 Aug; 142(4):529-37. PubMed ID: 18547320
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical tumor cell distribution pattern is a prognostically relevant parameter in patients with B-cell chronic lymphocytic leukemia.
    Jaksic O; Vrhovac R; Kusec R; Kardum MM; Pandzic-Jaksic V; Kardum-Skelin I; Planinc-Peraica A; Morabito F; Brugiatelli M; Jaksic B
    Haematologica; 2001 Aug; 86(8):827-36. PubMed ID: 11522539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia.
    Hewamana S; Lin TT; Rowntree C; Karunanithi K; Pratt G; Hills R; Fegan C; Brennan P; Pepper C
    J Clin Oncol; 2009 Feb; 27(5):763-9. PubMed ID: 19124804
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.
    Ma W; Kantarjian H; O'Brien S; Jilani I; Zhang X; Estrov Z; Ferrajoli A; Keating M; Giles F; Albitar M
    Cancer; 2008 Mar; 112(6):1306-12. PubMed ID: 18224667
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Distinctive immunoglobulin VH gene usage in Japanese patients with chronic lymphocytic leukemia.
    Koiso H; Yamane A; Mitsui T; Matsushima T; Tsukamoto N; Murakami H; Miyawaki S; Nojima Y; Karasawa M
    Leuk Res; 2006 Mar; 30(3):272-6. PubMed ID: 16159662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia.
    Vrbacky F; Nekvindova J; Rezacova V; Simkovic M; Motyckova M; Belada D; Painuly U; Jiruchova Z; Maly J; Krejsek J; Zak P; Cervinka M; Smolej L
    Neoplasma; 2014; 61(5):585-92. PubMed ID: 25030442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors.
    Rossi D; Sozzi E; Puma A; De Paoli L; Rasi S; Spina V; Gozzetti A; Tassi M; Cencini E; Raspadori D; Pinto V; Bertoni F; Gattei V; Lauria F; Gaidano G; Forconi F
    Br J Haematol; 2009 Jun; 146(1):64-75. PubMed ID: 19438485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia.
    Mainou-Fowler T; Porteous A; Nicolle A; Proctor SJ; Anderson JJ; Summerfield G
    Int J Oncol; 2008 Jul; 33(1):169-74. PubMed ID: 18575763
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression profile of galectin-1 and galectin-3 molecules in different subtypes of chronic lymphocytic leukemia.
    Asgarian-Omran H; Forghani P; Hojjat-Farsangi M; Roohi A; Sharifian RA; Razavi SM; Jeddi-Tehrani M; Rabbani H; Shokri F
    Cancer Invest; 2010 Aug; 28(7):717-25. PubMed ID: 20590446
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Laminin-332 (Laminin-5) is the major motility ligand for B cell chronic lymphocytic leukemia.
    Spessotto P; Zucchetto A; Degan M; Wasserman B; Danussi C; Bomben R; Perris R; Canzonieri V; Radillo O; Colombatti A; Gattei V
    Matrix Biol; 2007 Jul; 26(6):473-84. PubMed ID: 17482449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The GNAS1 T393C polymorphism and lack of clinical prognostic value in chronic lymphocytic leukemia.
    Kaderi MA; Murray F; Jansson M; Merup M; Karlsson K; Roos G; Aleskog A; Tobin G
    Leuk Res; 2008 Jun; 32(6):984-7. PubMed ID: 18006055
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antigen receptors and somatic hypermutation in B-cell chronic lymphocytic leukemia with Richter's transformation.
    Smit LA; van Maldegem F; Langerak AW; van der Schoot CE; de Wit MJ; Bea S; Campo E; Bende RJ; van Noesel CJ
    Haematologica; 2006 Jul; 91(7):903-11. PubMed ID: 16818277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia.
    Pratt G; Harding S; Holder R; Fegan C; Pepper C; Oscier D; Gardiner A; Bradwell AR; Mead G
    Br J Haematol; 2009 Jan; 144(2):217-22. PubMed ID: 19016722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
    Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
    Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia.
    Eisele L; Prinz R; Klein-Hitpass L; Nückel H; Lowinski K; Thomale J; Moeller LC; Dührsen U; Dürig J
    Eur J Haematol; 2009 Oct; 83(4):320-7. PubMed ID: 19500131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.